Clinical review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
The objective of this report is to perform a systematic review of the beneficial and harmful effects of belimumab 200 mg/ml subcutaneous injection in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, June 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of belimumab 200 mg/ml subcutaneous injection in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus |
|---|---|
| Physical Description: | 1 PDF file (126 pages) illustrations |